Do analysts recommend HOOK or TIL?

Instil Bio has a consensus price target of $66.00, indicating a potential upside of 716.83%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts plainly believe Instil Bio is more favorable than HOOKIPA Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HOOKIPA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is HOOK or TIL more profitable?

Instil Bio has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. Instil Bio's return on equity of -39.76% beat HOOKIPA Pharma's return on equity. Company Net Margins Return on Equity Return on Assets HOOKIPA Pharma -785.66% -120.09% -77.14% Instil Bio N/A -39.76% -22.38%

Do analysts prefer HOOK or XLO?

Xilio Therapeutics has a consensus price target of $28.00, suggesting a potential upside of 264.58%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than HOOKIPA Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HOOKIPA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts rate ATYR or HOOK?

aTyr Pharma currently has a consensus price target of $21.00, suggesting a potential upside of 4,650.06%. Given aTyr Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe aTyr Pharma is more favorable than HOOKIPA Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 HOOKIPA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend HOOK or MGX?

Metagenomi has a consensus target price of $9.00, indicating a potential upside of 597.67%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than HOOKIPA Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HOOKIPA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Is HOOK or MGX more profitable?

Metagenomi has a net margin of -384.61% compared to HOOKIPA Pharma's net margin of -785.66%. Metagenomi's return on equity of -51.23% beat HOOKIPA Pharma's return on equity. Company Net Margins Return on Equity Return on Assets HOOKIPA Pharma -785.66% -120.09% -77.14% Metagenomi -384.61% -51.23% -36.62%

Do analysts rate MREO or HOOK?

Mereo BioPharma Group currently has a consensus price target of $3.25, suggesting a potential upside of 965.57%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Mereo BioPharma Group is more favorable than HOOKIPA Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 HOOKIPA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

HOOKIPA Pharma (HOOK) Competitors

$1.15 0.00 (0.00%)

As of 06/2/2026

Compare

HOOK vs. TIL, XLO, ATYR, MGX, and MREO

Should you buy HOOKIPA Pharma stock or one of its competitors? MarketBeat compares HOOKIPA Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HOOKIPA Pharma include Instil Bio (TIL), Xilio Therapeutics (XLO), aTyr Pharma (ATYR), Metagenomi (MGX), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry.

How does HOOKIPA Pharma compare to Instil Bio?

HOOKIPA Pharma (NASDAQ:HOOK) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Instil Bio has a consensus price target of $66.00, indicating a potential upside of 716.83%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts plainly believe Instil Bio is more favorable than HOOKIPA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

63.9% of HOOKIPA Pharma shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 3.3% of HOOKIPA Pharma shares are owned by insiders. Comparatively, 47.0% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, HOOKIPA Pharma's average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
HOOKIPA Pharma	Neutral
Instil Bio	Neutral

HOOKIPA Pharma has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HOOKIPA Pharma	$9.35M	1.52	-$43.50M	-$3.54	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

HOOKIPA Pharma has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

Instil Bio has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. Instil Bio's return on equity of -39.76% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%
Instil Bio	N/A	-39.76%	-22.38%

Summary

Instil Bio beats HOOKIPA Pharma on 7 of the 12 factors compared between the two stocks.

How does HOOKIPA Pharma compare to Xilio Therapeutics?

HOOKIPA Pharma (NASDAQ:HOOK) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Xilio Therapeutics has higher revenue and earnings than HOOKIPA Pharma. Xilio Therapeutics is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HOOKIPA Pharma	$9.35M	1.52	-$43.50M	-$3.54	N/A
Xilio Therapeutics	$43.77M	1.15	-$35.04M	-$3.55	N/A

In the previous week, Xilio Therapeutics had 1 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 1 mentions for Xilio Therapeutics and 0 mentions for HOOKIPA Pharma. HOOKIPA Pharma's average media sentiment score of 0.00 equaled Xilio Therapeutics'average media sentiment score.

Company	Overall Sentiment
HOOKIPA Pharma	Neutral
Xilio Therapeutics	Neutral

HOOKIPA Pharma has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

Xilio Therapeutics has a consensus price target of $28.00, suggesting a potential upside of 264.58%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than HOOKIPA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

63.9% of HOOKIPA Pharma shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 3.3% of HOOKIPA Pharma shares are held by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Xilio Therapeutics has a net margin of -58.52% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Summary

Xilio Therapeutics beats HOOKIPA Pharma on 9 of the 15 factors compared between the two stocks.

How does HOOKIPA Pharma compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by company insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, aTyr Pharma had 3 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 3 mentions for aTyr Pharma and 0 mentions for HOOKIPA Pharma. aTyr Pharma's average media sentiment score of 0.19 beat HOOKIPA Pharma's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
aTyr Pharma	Neutral
HOOKIPA Pharma	Neutral

HOOKIPA Pharma has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	228.15	-$74.12M	-$0.73	N/A
HOOKIPA Pharma	$9.35M	1.52	-$43.50M	-$3.54	N/A

aTyr Pharma has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. aTyr Pharma's return on equity of -100.14% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%

aTyr Pharma has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, HOOKIPA Pharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

aTyr Pharma currently has a consensus price target of $21.00, suggesting a potential upside of 4,650.06%. Given aTyr Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe aTyr Pharma is more favorable than HOOKIPA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

aTyr Pharma beats HOOKIPA Pharma on 12 of the 17 factors compared between the two stocks.

How does HOOKIPA Pharma compare to Metagenomi?

HOOKIPA Pharma (NASDAQ:HOOK) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

In the previous week, Metagenomi had 1 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 1 mentions for Metagenomi and 0 mentions for HOOKIPA Pharma. HOOKIPA Pharma's average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score.

Company	Overall Sentiment
HOOKIPA Pharma	Neutral
Metagenomi	Neutral

HOOKIPA Pharma has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HOOKIPA Pharma	$9.35M	1.52	-$43.50M	-$3.54	N/A
Metagenomi	$25.21M	1.93	-$87.87M	-$2.30	N/A

63.9% of HOOKIPA Pharma shares are held by institutional investors. 3.3% of HOOKIPA Pharma shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Metagenomi has a consensus target price of $9.00, indicating a potential upside of 597.67%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than HOOKIPA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Metagenomi has a net margin of -384.61% compared to HOOKIPA Pharma's net margin of -785.66%. Metagenomi's return on equity of -51.23% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%
Metagenomi	-384.61%	-51.23%	-36.62%

HOOKIPA Pharma has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Summary

Metagenomi beats HOOKIPA Pharma on 12 of the 16 factors compared between the two stocks.

How does HOOKIPA Pharma compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Mereo BioPharma Group has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. Mereo BioPharma Group's return on equity of -81.28% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%

Mereo BioPharma Group has higher earnings, but lower revenue than HOOKIPA Pharma. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	97.37	-$41.88M	-$0.05	N/A
HOOKIPA Pharma	$9.35M	1.52	-$43.50M	-$3.54	N/A

Mereo BioPharma Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, HOOKIPA Pharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Mereo BioPharma Group's average media sentiment score of 0.00 equaled HOOKIPA Pharma'saverage media sentiment score.

Company	Overall Sentiment
Mereo BioPharma Group	Neutral
HOOKIPA Pharma	Neutral

Mereo BioPharma Group currently has a consensus price target of $3.25, suggesting a potential upside of 965.57%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Mereo BioPharma Group is more favorable than HOOKIPA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Mereo BioPharma Group beats HOOKIPA Pharma on 10 of the 14 factors compared between the two stocks.

Get HOOKIPA Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HOOK vs. The Competition

Export

Metric	HOOKIPA Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.18M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	-0.20	18.61	23.92	23.74
Price / Sales	1.52	298.40	507.55	107.94
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.27	8.04	10.28	6.78
Net Income	-$43.50M	$23.89M	$3.57B	$337.51M
7 Day Performance	N/A	-3.28%	0.28%	-2.34%
1 Month Performance	-2.54%	2.78%	3.27%	1.88%
1 Year Performance	-24.84%	36.03%	22.22%	25.55%

HOOKIPA Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HOOK HOOKIPA Pharma	N/A	$1.15 flat	N/A	-26.3%	$14.18M	$9.35M	N/A	160	Gap Down
TIL Instil Bio	2.1881 of 5 stars	$8.11 flat	$66.00 +713.8%	-75.4%	$55M	N/A	N/A	410	Positive News Analyst Downgrade
XLO Xilio Therapeutics	1.6731 of 5 stars	$8.20 -0.6%	$28.00 +241.5%	-21.6%	$54.24M	$43.77M	N/A	70	Positive News
ATYR aTyr Pharma	2.8359 of 5 stars	$0.52 -4.9%	$25.67 +4,835.9%	-91.8%	$53.60M	$190K	N/A	53	News Coverage
MGX Metagenomi	1.9613 of 5 stars	$1.33 +1.5%	$9.00 +576.7%	-25.4%	$49.32M	$25.21M	N/A	236

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HOOK) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HOOKIPA Pharma (HOOK) Competitors

HOOK vs. TIL, XLO, ATYR, MGX, and MREO

How does HOOKIPA Pharma compare to Instil Bio?

Summary

How does HOOKIPA Pharma compare to Xilio Therapeutics?

Summary

How does HOOKIPA Pharma compare to aTyr Pharma?

Summary

How does HOOKIPA Pharma compare to Metagenomi?

Summary

How does HOOKIPA Pharma compare to Mereo BioPharma Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOOK vs. The Competition

HOOKIPA Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HOOKIPA Pharma (HOOK) Competitors

HOOK vs. TIL, XLO, ATYR, MGX, and MREO

How does HOOKIPA Pharma compare to Instil Bio?

Do analysts recommend HOOK or TIL?

Do insiders and institutionals believe in HOOK or TIL?

Does the media prefer HOOK or TIL?

Which has higher valuation & earnings, HOOK or TIL?

Which has more volatility and risk, HOOK or TIL?

Is HOOK or TIL more profitable?

Summary

How does HOOKIPA Pharma compare to Xilio Therapeutics?

Which has higher valuation & earnings, HOOK or XLO?

Does the media refer more to HOOK or XLO?

Which has more risk and volatility, HOOK or XLO?

Do analysts prefer HOOK or XLO?

Do institutionals & insiders hold more shares of HOOK or XLO?

Is HOOK or XLO more profitable?

Summary

How does HOOKIPA Pharma compare to aTyr Pharma?

Do institutionals and insiders hold more shares of ATYR or HOOK?

Does the media favor ATYR or HOOK?

Which has higher earnings & valuation, ATYR or HOOK?

Is ATYR or HOOK more profitable?

Which has more volatility & risk, ATYR or HOOK?

Do analysts rate ATYR or HOOK?

Summary

How does HOOKIPA Pharma compare to Metagenomi?

Does the media favor HOOK or MGX?

Which has better earnings & valuation, HOOK or MGX?

Do insiders and institutionals have more ownership in HOOK or MGX?

Do analysts recommend HOOK or MGX?

Is HOOK or MGX more profitable?

Which has more volatility and risk, HOOK or MGX?

Summary

How does HOOKIPA Pharma compare to Mereo BioPharma Group?

Is MREO or HOOK more profitable?

Which has stronger earnings and valuation, MREO or HOOK?

Which has more volatility and risk, MREO or HOOK?

Do insiders & institutionals believe in MREO or HOOK?

Does the media refer more to MREO or HOOK?

Do analysts rate MREO or HOOK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOOK vs. The Competition

HOOKIPA Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools